Financial OutlookFor FY25, DocMorris expects sales growth of over 10% and adjusted EBITDA of minus CHF 35 to minus CHF 55m, which appears cautious compared to consensus expectations.
Market CompetitionThe outlook remains highly uncertain and could result in peer RDC gaining further share in the Germany Rx market as the rollout of ePrescription continues.
Share PerformanceFollowing a disappointing performance in 2024, especially in Rx, and in anticipation of a diluting capital increase, the shares have declined significantly.